June 11, 2025 — Daewoong Pharmaceutical announced today its strategic partnership with Salipro Biotech, a Swedish life sciences company, to collaborate on the development of innovative new drugs. The two companies signed a memorandum of understanding (MoU) to jointly advance research in this cutting-edge field.
Under the terms of the agreement, Salipro Biotech will provide its proprietary Salipro® platform to Daewoong Pharmaceutical. The Salipro® platform is a pioneering technology for stabilizing membrane proteins—an area that comprises more than 60% of known drug targets—making it possible to study these proteins in laboratory settings while maintaining their native structure and function. Membrane proteins have traditionally posed significant research challenges due to their structural instability; Salipro® has emerged as an innovative solution to overcome these limitations.
Salipro Biotech has a track record of collaborating with leading global pharmaceutical companies including Bayer, Sanofi, and Sumitomo. The partnership with Daewoong represents the company’s first collaboration with a Korean firm, marking a significant milestone. This alliance aims to not only expand Daewoong’s pipeline of membrane protein-based novel drugs but also lay the foundation for future global technology transfers.
Jens Frauenpfendt, CEO of Salipro Biotech, stated, “Our partnership with Daewoong is our first entry into the Korean market and presents a new chapter in drug discovery for both organizations. We hope the Salipro® platform will enable the research of high-difficulty target proteins and contribute to the development of innovative medicines worldwide.”
Daewoong CEO Park Sung-soo expressed optimism, saying, “By leveraging Salipro’s unique platform technology, we expect to lower the barriers to membrane protein research and elevate our drug development capabilities to new heights.”
